Centre for Respiratory Health, School of Biomedical Sciences, University of Western Australia, Nedlands, Western Australia, Australia.
Stem Cell Unit, Institute for Respiratory Health, Nedlands, Western Australia, Australia.
COPD. 2020 Feb;17(1):29-33. doi: 10.1080/15412555.2019.1711035. Epub 2020 Jan 10.
Chronic obstructive pulmonary disease (COPD) is characterised by a progressive pulmonary and systemic inflammation. Acute exacerbations of COPD (AECOPD) are associated with acute inflammation and infection, increase in the rates of morbidity and mortality. Previous proteomic studies have focussed on identifying proteins involved in COPD pathogenesis in samples collected from the lung (e.g. lung tissue biopsies, bronchoalveolar lavage and sputum) but not from blood of patients who experienced AECOPD. In this study, plasma was analysed by two independent quantitative proteomics techniques; isobaric tag for relative and absolute quantitation (iTRAQ) and multiple reaction monitoring (MRM) to identify differential expression of circulating proteins in patients with stable COPD (sCOPD) and AECOPD. Firstly, iTRAQ performed on pooled plasma samples from AECOPD, sCOPD, and healthy non-smoking controls (HC) revealed 15 differentially expressed proteins between the 3 groups. MRM subsequently performed on a separate cohort of AECOPD, sCOPD, and HC patients confirmed 9 proteins to be differentially expressed by AECOPD compared to HC (Afamin, alpha-1-antichymotrypsin, Apolipoprotein E, Beta-2-glycoprotein 1, Complement component C9, Fibronectin, Immunoglobulin lambda like polypeptide 5, Inter-alpha-trypsin inhibitor heavy chain H3, Leucine rich alpha-2-glycoprotein 1). Network analysis demonstrates that most of these proteins are involved in proteolysis regulation, platelet degranulation and cholesterol metabolism. In conclusion, several potential plasma biomarkers for AECOPD were identified in this study. Further validation studies of these proteins may elucidate their roles in the development of AECOPD.
慢性阻塞性肺疾病(COPD)的特征是肺部和全身炎症的进行性发展。COPD 的急性加重(AECOPD)与急性炎症和感染有关,增加了发病率和死亡率。先前的蛋白质组学研究主要集中在识别与 AECOPD 患者肺部(例如肺组织活检、支气管肺泡灌洗和痰液)样本中 COPD 发病机制相关的蛋白质,但未从经历 AECOPD 的患者的血液中识别。在这项研究中,通过两种独立的定量蛋白质组学技术(相对和绝对定量的同位素标记(iTRAQ)和多重反应监测(MRM))分析血浆,以鉴定稳定 COPD(sCOPD)和 AECOPD 患者循环蛋白的差异表达。首先,对来自 AECOPD、sCOPD 和健康非吸烟对照(HC)的合并血浆样本进行 iTRAQ 分析,发现 3 组之间有 15 个差异表达蛋白。随后在另一批 AECOPD、sCOPD 和 HC 患者中进行的 MRM 证实了 9 种蛋白质与 AECOPD 与 HC 相比差异表达(Afamin、alpha-1-抗胰蛋白酶、载脂蛋白 E、Beta-2-糖蛋白 1、补体成分 C9、纤维连接蛋白、免疫球蛋白 lambda 样多肽 5、α-1-胰蛋白酶抑制剂重链 H3、富含亮氨酸的 alpha-2-糖蛋白 1)。网络分析表明,这些蛋白质大多数参与蛋白水解调节、血小板脱颗粒和胆固醇代谢。总之,本研究中鉴定出了几个潜在的 AECOPD 血浆生物标志物。这些蛋白质的进一步验证研究可能阐明它们在 AECOPD 发展中的作用。